GE HealthCare stock raises 2026 outlook after Q3 beat

Published on 11/05/2026 at 02:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GE HealthCare stock traded at 76.77 euros on Lang & Schwarz late Wednesday. The company raised its full-year outlook after strong third-quarter growth.

Guidance rises after strong quarter

Third-quarter revenue increased 7.2 percent, while organic growth reached 6.2 percent.
GE HealthCare raised its full-year adjusted EPS outlook to 4.95 to 5.05 US dollars.
Pharmaceutical Diagnostics delivered the fastest segment growth in the quarter.

GE HealthCare, US36266G1076, Illustration mit AI erstellt.

GE HealthCare raised its full-year 2026 outlook after reporting stronger third-quarter results on October 28. In its third-quarter financial release, the medical technology company reported revenue growth across all segments and higher profitability.

Revenue and margins accelerate

Revenue for the quarter ended September 30 rose 7.2 percent year over year to 5.5 billion US dollars. Organic revenue growth reached 6.2 percent, while adjusted EBIT increased to 913 million US dollars from 761 million US dollars a year earlier.

Adjusted EBIT margin widened to 16.6 percent from 14.8 percent. Adjusted earnings per share rose to 1.34 US dollars from 1.07 US dollars, while diluted earnings per share reached 1.36 US dollars.

Pharmaceutical Diagnostics reported the strongest organic growth among the main segments at 13.8 percent. Advanced Imaging Solutions grew organically by 4.5 percent, and Patient Care Solutions increased organic revenue by 8.8 percent.

Full-year targets move higher

Management raised its full-year organic revenue growth outlook to approximately 4.0 percent from a previous range of 3.0 percent to 4.0 percent. The adjusted EBIT margin target moved to 15.5 percent to 15.7 percent, and adjusted EPS guidance increased to 4.95 to 5.05 US dollars from 4.80 to 5.00 US dollars.

The company also lifted its free cash flow outlook to more than 1.6 billion US dollars. The quarter included 793 million US dollars of free cash flow and a 55 million US dollar tariff refund, which is a relevant one-time factor in the cash-flow comparison.

Late trading remains the market signal

GE HealthCare stock traded at 76.77 euros on Lang & Schwarz at 11:00 p.m. CET on Wednesday, November 4. Investors can follow the real-time quote of GE HealthCare stock on the company page.

Medical technology portfolio

GE HealthCare develops and supplies medical technology across Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions. Its portfolio includes imaging systems, ultrasound, patient-care products, pharmaceutical diagnostics and software for healthcare providers, with the company headquartered in the United States. The business competes in global medical technology markets with companies such as Siemens Healthineers, Philips and Canon Medical, while its portfolio spans several healthcare technology categories rather than a single device niche.

The Euro Stoxx 50 provides the broader European market context for investors tracking healthcare and industrial technology shares.

More news and analyses on GE HealthCare stock.